Clinical Trial Update: Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating talazoparib with temozolomide in younger patients with refractory or recurrent solid tumors; study completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasm
• Childhood Central Nervous System Neoplasm
• Childhood Solid Neoplasm
• Ewing Sarcoma Peripheral Primitive Neuroectodermal Tumor
• Malignant Solid Neoplasm
• Solid Neoplasm

Drugs mentioned

• Talazoparib (talazoparib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Solid Neoplasm, Childhood Solid Neoplasm | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-03-26